Amgen’s Pavblu has been the most successful US biosimilar launch by any manufacturer to date, with more than $600 million in net sales in 2025. The February 3rd earnings report released by Amgen underscore the major success of its Pavblu launch, the first biosimilar competitor to Eylea. For the full year 2025, US net sales … Continue reading Update on Amgen’s Pavblu Launch Success